Royal London Asset Management Ltd. Purchases 9,454 Shares of Hologic, Inc. (NASDAQ:HOLX)

Royal London Asset Management Ltd. lifted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 344,465 shares of the medical equipment provider's stock after purchasing an additional 9,454 shares during the quarter. Royal London Asset Management Ltd. owned 0.15% of Hologic worth $24,832,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. General Partner Inc. purchased a new stake in Hologic in the fourth quarter worth approximately $26,000. Groupama Asset Managment boosted its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. First Horizon Advisors Inc. raised its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Hologic Stock Up 1.1 %

Shares of NASDAQ HOLX traded up $0.68 during mid-day trading on Wednesday, hitting $61.48. 1,465,933 shares of the stock traded hands, compared to its average volume of 1,756,362. The company has a market cap of $13.80 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The stock has a fifty day moving average price of $65.70 and a 200-day moving average price of $73.66. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. BNP Paribas upgraded Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Morgan Stanley cut their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Stephens reiterated an "overweight" rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has an average rating of "Hold" and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.